Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research

References

• Fernandez O, Martin R, Rovira A, et al. Biomarkers in multiple sclerosis: an update for 2014. Rev Neurol. 2014;58(12):553–570.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Criste G, Trapp B, Dutta R. Axonal loss in multiple sclerosis: causes and mechanisms. Handb Clin Neurol. 2014;122:101–113.
   PubMedGoogle Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2095–2128.
   PubMed Web of Science ®Google Scholar
• Mortality GBD. Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5): 1175–1189.
   PubMed Web of Science ®Google Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183–193.
   PubMed Web of Science ®Google Scholar
• Chari DM. Remyelination in multiple sclerosis. Int Rev Neurobiol. 2007;79:589–620.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1): 121–127.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• Martinez MA, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5): 550–561.
   PubMed Web of Science ®Google Scholar
• Dickens AM, Larkin JR, Griffin JL, et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology. 2014;83(17): 1492–1499.
   PubMed Web of Science ®Google Scholar
• Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13(1):113–126.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3): 278–286.
   PubMed Web of Science ®Google Scholar
• Miller AE. Multiple sclerosis: where will we be in 2020? Mt Sinai J Med. 2011;78(2):268–279.
   PubMed Web of Science ®Google Scholar
• Ottens AK, Kobeissy FH, Golden EC, et al. Neuroproteomics in neurotrauma. Mass Spectrom Rev. 2006;25(3): 380–408.
   PubMed Web of Science ®Google Scholar
• Kroksveen AC, Opsahl JA, Guldbrandsen A, et al. Cerebrospinal fluid proteomics in multiple sclerosis. Biochim Biophys Acta. 2015;1854(7):746–756.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Dai DL, Hollander Z, et al. Serum proteomics in multiple sclerosis disease progression. J Proteomics. 2015;118:2–11.
   PubMed Web of Science ®Google Scholar
• Liguori M, Qualtieri A, Tortorella C, et al. Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. PLoS One. 2014;9(8): e103984.
   PubMed Web of Science ®Google Scholar
• Füvesi J, Hanrieder J, Bencsik K, et al. Proteomic analysis of cerebrospinal fluid in a fulminant case of multiple sclerosis. Int J Mol Sci. 2012;13(6): 7676–7693.
   PubMed Web of Science ®Google Scholar
• Jia Y, Wu T, Jelinek CA, et al. Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clin Proteomics. 2012;9(1): 9.
   PubMedGoogle Scholar
• Raphael I, Mahesula S, Kalsaria K, et al. Microwave and magnetic (M2) proteomics of the experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Electrophoresis. 2012;33(24): 3810–3819.
   PubMed Web of Science ®Google Scholar
• Junker A. Pathophysiology of translational regulation by microRNAs in multiple sclerosis. FEBS Lett. 2011;585(23):3738–3746.
   PubMed Web of Science ®Google Scholar
• Wallin MT, Oh U, Nyalwidhe J, et al. Serum proteomic analysis of a pre-symptomatic multiple sclerosis cohort. Eur J Neurol. 2015;22(3):591–599.
   PubMed Web of Science ®Google Scholar
• Zare-Shahabadi A, Renaudineau Y, Rezaei N. MicroRNAs and multiple sclerosis: from physiopathology toward therapy. Expert Opin Ther Targets. 2013;17(12):1497–1507.
   PubMed Web of Science ®Google Scholar
• Guerau-de-Arellano M, Smith KM, Godlewski J, et al. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain. 2011;134(Pt 12): 3578–3589.
   PubMed Web of Science ®Google Scholar
• Junker A, Krumbholz M, Eisele S, et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009;132(Pt 12): 3342–3352.
   PubMed Web of Science ®Google Scholar
• Thamilarasan M, Koczan D, Hecker M, et al. MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. Autoimmun Rev. 2012;11(3):174–179.
   PubMed Web of Science ®Google Scholar
• Koch MW, Metz LM, Kovalchuk O. Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis. Trends Mol Med. 2013;19(1):23–30.
   PubMed Web of Science ®Google Scholar
• Reijerkerk A, Lopez-Ramirez MA, Van Het Hof B, et al. MicroRNAs regulate human brain endothelial cell-barrier function in inflammation: implications for multiple sclerosis. J Neurosci. 2013;33(16): 6857–6863.
   PubMed Web of Science ®Google Scholar
• Keller A, Leidinger P, Steinmeyer F, et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler. 2014;20(3):295–303.
   Google Scholar
• Fenoglio C, Cantoni C, De Riz M, et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett. 2011;504(1):9–12.
   PubMed Web of Science ®Google Scholar
• Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10(12): 1252–1259.
   PubMed Web of Science ®Google Scholar
• Fenoglio et al. Neurosci Lett. 2011;504(1):9–12.
   PubMed Web of Science ®Google Scholar
• Zhu S, Pan W, Song X, et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-[alpha]. Nat Med. 2012;18(7): 1077–1086.
   PubMed Web of Science ®Google Scholar
• Gandhi R, Healy B, Gholipour T, et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013;73(6): 729–740.
   PubMed Web of Science ®Google Scholar
• Søndergaard HB, Hesse D, Krakauer M, et al. Differential microRNA expression in blood in multiple sclerosis. Mult Scler. 2013;19(14):1849–1857.
   PubMed Web of Science ®Google Scholar
• Waschbisch A, Atiya M, Linker RA, et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One. 2011;6(9):e24604.
   PubMed Web of Science ®Google Scholar
• Shapshak P. Molecule of the month: miRNA and multiple sclerosis. Bioinformation. 2013;9(17):847–848.
   PubMedGoogle Scholar
• Dutta R, Chomyk AM, Chang A, et al. Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR‐124 and reduced AMPA receptors. Ann Neurol. 2013;73(5): 637–645.
   PubMed Web of Science ®Google Scholar
• Noorbakhsh F, Ellestad KK, Maingat F, et al. Impaired neurosteroid synthesis in multiple sclerosis. Brain. 2011;134(Pt 9): 2703–2721.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wu J, Zheng M, et al. Specification and maintenance of oligodendrocyte precursor cells from neural progenitor cells: involvement of microRNA-7a. Mol Biol Cell. 2012;23(15):2867–2878.
   PubMed Web of Science ®Google Scholar
• Lindberg RL, Hoffmann F, Mehling M, et al. Altered expression of miR‐17‐5p in CD4+ lymphocytes of relapsing–remitting multiple sclerosis patients. Eur J Immunol. 2010;40(3):888–898.
   PubMed Web of Science ®Google Scholar
• Prinz M, Priller J, Sisodia SS, et al. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci. 2011;14(10):1227–1235.
   PubMed Web of Science ®Google Scholar
• Ponomarev ED, Veremeyko T, Weiner HL. MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia. 2013;61(1):91–103.
   PubMed Web of Science ®Google Scholar
• Ponomarev ED, Veremeyko T, Barteneva N, et al. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med. 2011;17(1):64–70.
   PubMed Web of Science ®Google Scholar
• Soreq H, Wolf Y. NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mol Med. 2011;17(10):548–555.
   PubMed Web of Science ®Google Scholar
• Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557–1569.
   PubMed Web of Science ®Google Scholar
• Lescher J, Paap F, Schultz V, et al. MicroRNA regulation in experimental autoimmune encephalomyelitis in mice and marmosets resembles regulation in human multiple sclerosis lesions. J Neuroimmunol. 2012;246(1–2): 27–33.
   PubMed Web of Science ®Google Scholar
• Jernas M, Malmestrom C, Axelsson M, et al. MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). BMC Immunol. 2013;14:32.
   PubMed Web of Science ®Google Scholar
• Lorenzi JC, Brum DG, Zanette DL, et al. miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients. Int J Neurosci. 2012;122(8): 466–471.
   PubMed Web of Science ®Google Scholar
• De Santis G, Ferracin M, Biondani A, et al. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol. 2010;226(1–2): 165–171.
   PubMed Web of Science ®Google Scholar
• Smith KM, Guerau-de-Arellano M, Costinean S, et al. miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol. 2012;189(4): 1567–1576.
   PubMed Web of Science ®Google Scholar
• Sievers C, Meira M, Hoffmann F, et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol. 2012;144(1):70–79.
   PubMed Web of Science ®Google Scholar
• Moore CS, Rao VT, Durafourt BA, et al. miR‐155 as a multiple sclerosis–relevant regulator of myeloid cell polarization. Ann Neurol. 2013;74(5): 709–720.
   PubMed Web of Science ®Google Scholar
• Jin XF, Wu N, L W, et al. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33(5):601–613.
   PubMed Web of Science ®Google Scholar
• Cox MB, Cairns MJ, Gandhi KS, et al. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One. 2010;5(8): e12132.
   PubMed Web of Science ®Google Scholar
• Siegel SR, Mackenzie J, Chaplin G, et al. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep. 2012;39(5):6219–6225.
   PubMed Web of Science ®Google Scholar
• Kobeissy FH, Gulbakan B, Alawieh A, et al. Post-genomics nanotechnology is gaining momentum: nanoproteomics and applications in life sciences. Omics. 2014;18(2): 111–131.
   PubMed Web of Science ®Google Scholar
• Hecker M, Thamilarasan M, Koczan D, et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Mol Sci. 2013;14(8): 16087–16110.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Due DL. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):205–214.
   PubMedGoogle Scholar
• Hanieh H, Alzahrani A. MicroRNA-132 suppresses autoimmune encephalomyelitis by inducing cholinergic anti-inflammation: a new Ahr-based exploration. Eur J Immunol. 2013;43(10):2771–2782.
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Beynon V, Mittal A, et al. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2011;187(5):2213–2221.
   PubMed Web of Science ®Google Scholar
• Zhang J, Cheng Y, Cui W, et al. MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;266(1–2):56–63.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288–299.
   PubMed Web of Science ®Google Scholar
• Cantorna MT. Mechanisms underlying the effect of vitamin D on the immune system. Proc Nutr Soc. 2010;69(3):286–289.
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA. 1996;93(15):7861–7864.
   PubMed Web of Science ®Google Scholar
• Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132(Pt 5):1146–1160.
   PubMed Web of Science ®Google Scholar
• Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–2838.
   PubMed Web of Science ®Google Scholar
• Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1): 60–65.
   PubMed Web of Science ®Google Scholar
• Koch MW, Metz LM, Kovalchuk O. Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol. 2013;9(1):35–43.
   PubMed Web of Science ®Google Scholar
• Carlson NG, Rose JW. Vitamin D as a clinical biomarker in multiple sclerosis. Expert Opin Med Diagn. 2013;7(3):231–242.
   PubMedGoogle Scholar
• Khoo AL, Joosten I, Michels M, et al. 1,25-dihydroxyvitamin D3 inhibits proliferation but not the suppressive function of regulatory T cells in the absence of antigen-presenting cells. Immunology. 2011;134(4): 459–468.
   PubMed Web of Science ®Google Scholar
• Jeffery LE, Burke F, Mura M, et al. 1,25-dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183(9): 5458–5467.
   PubMed Web of Science ®Google Scholar
• Farez MF, Fiol MP, Gaitan MI, et al. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):26–31.
   PubMed Web of Science ®Google Scholar
• Joshi S, Pantalena LC, Liu XK, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol. 2011;31(17): 3653–3669.
   PubMed Web of Science ®Google Scholar
• Jorde R, Svartberg J, Joakimsen RM, et al. Plasma profile of microRNA after supplementation with high doses of vitamin D3 for 12 months. BMC Res Notes. 2012;5:245.
   PubMedGoogle Scholar
• Yang M, Qin Z, Zhu Y, et al. Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression. Mol Neurobiol. 2013;47(3): 946–956.
   PubMed Web of Science ®Google Scholar
• Cramer SP, Simonsen H, Frederiksen JL, et al. Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. NeuroImage Clin. 2014;4:182–189.
   PubMed Web of Science ®Google Scholar
• Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012;7:185–217.
   PubMed Web of Science ®Google Scholar
• Van Der Voorn P, Tekstra J, Beelen RH, et al. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol. 1999;154(1):45–51.
   PubMed Web of Science ®Google Scholar
• Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233(1–2):183–198.
   PubMed Web of Science ®Google Scholar
• Skillback T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83(21): 1945–1953.
   PubMed Web of Science ®Google Scholar
• Anderson KJ, Scheff SW, Miller KM, et al. The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J Neurotrauma. 2008;25(9): 1079–1085.
   PubMed Web of Science ®Google Scholar
• Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(4): 467–472.
   PubMed Web of Science ®Google Scholar
• Gresle MM, Liu Y, Dagley LF, et al. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2014;85(11): 1209–1213.
   PubMed Web of Science ®Google Scholar
• Bartos A, Fialova L, Soukupova J, et al. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand. 2007;116(2):100–107.
   PubMed Web of Science ®Google Scholar
• Hein Nee Maier K, Kohler A, Diem R, et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett. 2008;436(1): 72–76.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15): 1322–1329.
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol. 2004;251(4):414–420.
   PubMed Web of Science ®Google Scholar
• Guimaraes I, Cardoso MI, Sa MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler. 2006;12(3):354–356.
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek H, Stelmasiak Z. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. J Neural Transm. 2005;112(6):797–803.
   PubMed Web of Science ®Google Scholar
• Gironi M, Bergami A, Brambilla E, et al. Immunological markers in multiple sclerosis. Neurol Sci. 2000;21(4 Suppl 2): S871–875.
   PubMedGoogle Scholar
• Furlan R, Rovaris M, Martinelli Boneschi F, et al. Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol. 2005;165(1–2): 192–200.
   PubMed Web of Science ®Google Scholar
• Maimone D, Gregory S, Arnason BG, et al. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991;32(1):67–74.
   PubMed Web of Science ®Google Scholar
• Sharief MK, Noori MA, Ciardi M, et al. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol. 1993;43(1–2):15–21.
   PubMed Web of Science ®Google Scholar
• Al-Shammri S, Rawoot P, Azizieh F, et al. Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis. J Neurol Sci. 2004;222(1–2): 21–27.
   PubMed Web of Science ®Google Scholar
• Axelsson M, Malmestrom C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014;20(1): 43–50.
   PubMed Web of Science ®Google Scholar
• Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci. 2011;305(1–2):1–10.
   PubMed Web of Science ®Google Scholar
• Dimisianos N, Rodi M, Kalavrizioti D, et al. Cytokines as biomarkers of treatment response to IFNβ in relapsing-remitting multiple sclerosis. Mult Scler Int. 2014;2014:436764.
   Google Scholar
• Colomba P, Fontana S, Salemi G, et al. Identification of biomarkers in cerebrospinal fluid and serum of multiple sclerosis patients by immunoproteomics approach. Int J Mol Sci. 2014;15(12): 23269–23282.
   PubMed Web of Science ®Google Scholar
• Duranti F, Pieri M, Centonze D, et al. Determination of kFLC and K index in cerebrospinal fluid: A valid alternative to assessintrathecal immunoglobulin synthesis. J Neuroimmunol. 2013;263(1):116–120.
   PubMed Web of Science ®Google Scholar
• Sand IK. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol. 2015;28(3):193–205.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Ej T, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62(6): 865–870.
   PubMed Web of Science ®Google Scholar
• Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol. 2006;180(1–2):17–28.
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology. 2008;70(13 Pt 2): 1079–1083.
   PubMed Web of Science ®Google Scholar
• Hassan-Smith G, Durant L, Tsentemeidou A, et al. High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. J Neuroimmunol. 2014;276(1): 175–179.
   PubMed Web of Science ®Google Scholar
• Senel M, Tumani H, Lauda F, et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One. 2014;9(4): e88680.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–815.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451): 2106–2112.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–1489.
   PubMed Web of Science ®Google Scholar
• Gilli F, Bertolotto A, Sala A, et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain. 2004;127(Pt 2): 259–268.
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology. 2003;60(4): 634–639.
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9(7): 740–750.
   PubMed Web of Science ®Google Scholar
• Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000;48(5): 706–712.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362(9391): 1184–1191.
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Sala A, Malucchi S, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry. 2004;75(9): 1294–1299.
   PubMed Web of Science ®Google Scholar
• Karussis D, Teitelbaum D, Sicsic C, AC001 Multi-Center Israeli Study Group. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol. 2010;220(1–2):125–130.
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I, Ferenczi LZ, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol. 2006;13(8):887–895.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007;356(4): 371–378.
   PubMed Web of Science ®Google Scholar
• Petzold A, Sharpe LT, Keir G. Spectrophotometry for cerebrospinal fluid pigment analysis. Neurocrit Care. 2006;4(2):153–162.
   PubMed Web of Science ®Google Scholar
• Elkabes S, Li H. Proteomic strategies in multiple sclerosis and its animal models. Proteomics Clin Appl. 2007;1(11):1393–1405.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22): 1914–1922.
   PubMed Web of Science ®Google Scholar
• Berven FS, Kroksveen AC, Berle M, et al. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl. 2007;1(7): 699–711.
   PubMed Web of Science ®Google Scholar
• West-Nielsen M, Hogdall EV, Marchiori E, et al. Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem. 2005;77(16):5114–5123.
   PubMed Web of Science ®Google Scholar
• Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med CCLM/FESCC. 2006;44(6):750–759.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431–440.
   PubMed Web of Science ®Google Scholar